1. Home
  2. SPRO vs NLOP Comparison

SPRO vs NLOP Comparison

Compare SPRO & NLOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.58

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

NLOP

Net Lease Office Properties of Beneficial Interest

HOLD

Current Price

$11.58

Market Cap

176.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
NLOP
Founded
2013
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
156.3M
176.7M
IPO Year
2017
2022

Fundamental Metrics

Financial Performance
Metric
SPRO
NLOP
Price
$1.58
$11.58
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.9M
175.0K
Earning Date
05-13-2026
05-19-2026
Dividend Yield
N/A
52.20%
EPS Growth
111.81
N/A
EPS
N/A
1.69
Revenue
$66,802,000.00
$118,915,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$300.00
N/A
P/E Ratio
N/A
$6.93
Revenue Growth
39.24
N/A
52 Week Low
$1.52
$10.95
52 Week High
$3.08
$34.31

Technical Indicators

Market Signals
Indicator
SPRO
NLOP
Relative Strength Index (RSI) 26.06 53.97
Support Level N/A $11.60
Resistance Level $2.45 $12.26
Average True Range (ATR) 0.14 0.30
MACD -0.05 0.08
Stochastic Oscillator 8.93 77.51

Price Performance

Historical Comparison
SPRO
NLOP

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About NLOP Net Lease Office Properties of Beneficial Interest

Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns, operates, and finances a diversified portfolio of office properties mainly leased to corporate tenants on a single-tenant, net-lease basis. The company operates as a single operating and reportable segment focused on owning and managing office properties that generate revenue mainly from long-term lease agreements with tenants.

Share on Social Networks: